

AASLD Nov. 15-19, 2024
The Liver Meeting®



SAN DIEGO, CA

Industry Programming Guide



#TLM24

AASLD
The Liver Meeting®



MAKING AN IMPACT, TOGETHER, AT THE LIVER MEETING

— SAVE THE DATE —
NOVEMBER 7–11, 2025

Washington, DC • www.aasld.org/the-liver-meeting



Stay Informed: Join The
Liver Meeting Email List!

Exhibit Hall Map 4

Satellite Symposia 7

TLM Theaters 23

PER LIVER CANCER TUMOR BOARD:

How Do Evolving Data for Immune-Based Strategies in

RESECTABLE AND UNRESECTABLE HCC IMPACT

Multidisciplinary Patient Management Today, and Tomorrow?

November 16, 2024

7:30–9:30 PM PT



Scan the QR code or visit the link below to learn more

gotoper.com/courses/liver-cancer-meeting



Presented for attendees of The Liver Meeting[®] 2024. This event/function is provided by PER and supported by AstraZeneca. This is not an official event/function of the American Association for the Study of Liver Diseases.

Exhibit Hall Map

TLM
Theater
1



1652	1553
1650	1551

1450	1351
------	------

1451

1745

1547
1545

1445

1239

1843
1841
1839

1739

1645

1539



To Business Suites & Poster Hall

1833
1831
1829
1825

1832	1731
1830	

1633	
1730	1629
1726	1625
1724	

1529

1433
1431

1329

1826	1727
1824	1725

1624	1523
1622	

1517

1427
1425

1325	
1422	1323
1420	1321

1225

1617
1615
1611

1517

1419
1417

1211

1610	1513
	1511

1413
1411

1305	1304
------	------



B2 Hall Entrance



1257
1255

1157
1155
1153

1156 1057
1154 1055
846 1051
1150

1056 957
1054 955
1052 953
951



TLM Theater 2

850 751
848 749
846 747

750
748
746
744

1246 1149
1147

1045

945

839

739

738

1238 1141
1139



939

To General Session



1129

1133
1031

727

732
730
728
726
724
722
720
718
716
714
712
710

1224 1121
1222
1220

1025
1023

1022 921
1020
1018 919
1016 917

822 721
820
818 719

1117
1115
1111

1019
1017

911

711
AASLD Hub

1205 1204 1203 1105



B1 Hall Entrance



Scan the QR code to view the interactive map online.

Visit the Exhibit Hall:

Saturday, Nov. 16

6:00 PM - 7:30 PM

Opening Reception in Exhibit Hall

Sunday, Nov. 17

9:30 AM - 4:30 PM

Monday, Nov. 18

9:30 AM - 4:30 PM

Why Register?

Join the touch online
community for FREE access



**Practical
articles**



**Expert
Interviews**



**News and
insights**

**touch™
ENDOCRINOLOGY**

**touch™
ONCOLOGY**

**touch™
INFECTIOUS DISEASES**



Satellite Symposia

Friday, Nov. 15

Timing Is Everything: Optimizing Diagnosis and Personalized Treatment With First-Line Immunotherapy Plus Chemotherapy in Advanced Biliary Tract Cancer

12:30 - 2:00 PM

Convention Center, Ballroom 20 D

SUPPORTED BY: AstraZeneca

ORGANIZED BY: Answers in CME

CME: Maximum of 1.0 AMA PRA Category 1 Credits

PRESENTERS: Aiwu Ruth He, MD, PhD; Lewis R. Roberts, MB, ChB, PhD

Two leading experts in biliary tract cancer—an oncologist and a hepatologist—will share best practices for early diagnosis and first-line treatment of advanced BTC with immunotherapy plus chemotherapy combinations, including multidisciplinary strategies to enhance patient quality of life on and off treatment.

LEARNING OBJECTIVES

- Identify best practices for early recognition of patients with biliary tract cancer (BTC) to optimize diagnosis
- Discuss multidisciplinary strategies to address key diagnostic challenges in advanced BTC
- Describe the clinical profiles of immune checkpoint inhibitor (ICI) plus chemotherapy combinations for the first-line treatment for advanced BTC
- Outline multidisciplinary approaches to enhance care of patients with advanced BTC on an ICI plus chemotherapy combination

www.answersincme.com/93641753



Download the mobile app for updates, and add these events to your schedule.

Free CME/CE Dinner Symposium

Provided By:  medtelligenceSM

The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care

Join us to learn about advances in the treatment of MASH, including the basis for and benefits of pharmacologic strategies for modifying body weight.



November 16, 2024 | 7:30 PM - 9:30 PM PT



Marriott Marquis San Diego Marina
333 W Harbor Dr, San Diego, CA 92101,
Grand Ballroom 1, 2, 5 (Lobby Level), United States

This symposium will help you improve your practice by providing practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management, including the role of incretin agonists.

CHAIR



Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer
Director of the Steatotic Liver Program
Chief of Transplant Hepatology
Arizona Liver Health
Phoenix, AZ



PANELISTS



Amreen M. Dinani, MD, FRCPC
Associate Professor of Medicine
Gastroenterology
Duke University School of Medicine
Durham, NC

Register Now



Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAF
Director, Campbell University Health Center
Chair and Associate Professor of Family Medicine
Buies Creek, NC



Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Medtelligence and supported by Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. This is not an official event/function of the American Association for the Study of Liver Diseases.

Commercial Support:
This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc.



Updates in the Patient Journey: Autoimmune Hepatitis and Primary Sclerosing Cholangitis

12:30 - 2:00 PM

Convention Center, Ballroom 20 A

SUPPORTED BY: Perspectum Ltd

ORGANIZED BY: HealthProMatch

CME: Maximum 1.5 AMA PRA Category 1 Credits

PRESENTERS: Craig S. Lammert, MD; John M. Vierling, MD, FACP, FAASLD, AGAF; Cynthia Bunes, JD, MBA

This is an update on autoimmune liver disease, in particular AIH and PSC. There is a focus on the current evidence-base around precision markers and NITs in diagnosing, monitoring, and prognosticating autoimmune disease and new treatments on the horizon. Finally, we explore how patient advocate groups can help inform PROMS and approaches to research.

LEARNING OBJECTIVES

- Describe and understand the revised classification and available decision-aids in immune-mediated liver disease, in particular AIH and PSC
- Critically appraise current evidence-base for precision markers in blood tests and imaging for diagnosis, monitoring and prognosticating in patients with autoimmune liver disease
- Reflect upon patient narratives and suggestions from patient advocate groups regarding treatment strategies and approaches to research.

<https://healthpromatch.com/cme-event-nov-15/>

Primary Biliary Cholangitis: Real-World Outcomes in Context

12:30 - 2:00 PM

Convention Center, Ballroom 20 BC

SUPPORTED BY: Intercept

ORGANIZED BY: Medscape Education

CME: 1.25 CME and 1.25 Nursing

PRESENTERS: Kris V. Kowdley MD, AGAF, FAASLD, FACP, FACG; David E. Jones, MD, PhD; Alejandra Maria Villamil, MD

This activity seeks to empower clinicians to effectively manage your patients with primary biliary cholangitis (PBC) and improve their outcomes. By enhancing your competence in monitoring disease activity and progression, identifying when there is a need for second-line therapy,

and individualizing treatment for your patients, you will be better able to address delays in initiating appropriate therapy. Additionally, by providing real-world evidence on clinical outcomes beyond biomarkers and liver enzymes, such as decompensation, transplantation, and mortality, you will be better equipped to make more informed decisions about second-line therapy options.

LEARNING OBJECTIVES

- Have greater competence related to monitoring PBC disease activity and progression in practice
- Have greater competence related to recognizing patients with PBC who require second-line therapy
- Have greater competence related to selecting evidence-based second-line therapies for patients with PBC
- Demonstrate greater confidence in their ability to tailor treatments for patients with PBC

<https://na.eventscloud.com/ereg/newreg.php?eventid=815748&>

Challenging Cases in Navigating Diagnostic Complexities and Strategies for Improved Management of Adults With Cholestatic Liver Diseases

7:30 – 9:30 PM

Marriott Marquis, Grand Ballroom 125 (Lobby Level)

SUPPORTED BY: Ipsen

ORGANIZED BY: Medscape Education

CME: Maximum of 1.50 AMA PRA Category 1 Credits

PRESENTERS: Gideon Hirschfield, MB BChir, FRCP, PhD; Amal Aqul, MD; Raj Vuppalanchi, MD

There are delays in diagnosing, initiating treatment, and appropriately advancing therapy for adult patients with cholestatic liver diseases such as primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC). This case-based symposium will present key concepts, current evidence, and best practices for the early diagnosis and management of cholestatic liver diseases in adult patients.

Learning Objectives:

- Increased **knowledge** regarding the clinical presentation of cholestatic liver disease in adults
- Greater **competence** related to using testing to identify different types of cholestatic liver diseases



- Increased **knowledge** regarding the safety and efficacy of current treatments for cholestatic liver diseases
- Greater **competence** related to selecting treatments for patients with rare types of cholestatic liver diseases

www.medscape.org/symposium/cholestatic-liver

Saturday, Nov. 16

Discussing Key Clinical Decisions in Managing Primary Biliary Cholangitis

12:30 - 2:00 PM

Convention Center, Ballroom 20 BC

SUPPORTED BY: Gilead Sciences, Inc.

ORGANIZED BY: Medscape Education

CME: Maximum of 1.25 AMA PRA Category 1 Credits

PRESENTERS: Maria Morais, RN; Gideon Hirschfield, MB, BChir, FRCP, PhD; Sonal Kumar, MD, MPH

Therapy goals for primary biliary cholangitis (PBC) are increasingly individualized and aspire to rapidly achieve normalization of biochemical markers. At the same time, novel therapies are poised to change the PBC treatment landscape. Attend this interactive, case-based symposium to learn from expert faculty about novel emerging treatments that may offer patients improved outcomes in PBC. In addition, a patient advocate will join our faculty to relate her experience of living with PBC, the burden of symptoms and impact on quality of life, and how patients and clinicians can best work together to achieve treatment goals.

LEARNING OBJECTIVES

- Have increased knowledge regarding the data from phase 3 clinical trials of treatments for PBC
- Have greater competence related to evaluating the risk for progressive PBC
- Demonstrate greater confidence in their ability to determine PBC treatment goals that consider biochemical response and patient-reported outcomes

www.medscape.org/sympo/pcb-debate

Saturday, Nov. 16 continued on page 13

A Deep Dive into MASH: Exploring the Role of Metabolic Dysfunction in Disease Pathophysiology

Novo Nordisk invites you to join our expert faculty and your colleagues for this sponsored educational program.



Faculty
Naim Alkhouri, MD, FAASLD, DABOM
Chief Medical Officer
Director, Steatotic Liver Program
Chief of Transplant Hepatology
Arizona Liver Health
Chandler, AZ



Sunday,
November 17, 2024
Time: 3:30 PM – 4:15 PM PT



TLM Theater #1
Exhibit Hall B
San Diego Convention Center
Novo Nordisk Booth #1529

Refreshments will be provided^a

Plan to arrive early to reserve your seat. Space is limited.

Program Description

This presentation will examine MASH (metabolic dysfunction-associated steatohepatitis) and the role of cardiometabolic dysfunction in disease development and progression. We will also discuss current AASLD guidelines regarding screening and management of patients at high-risk for advanced disease.

This program is sponsored by Novo Nordisk.

This is a disease awareness education presentation; it will not be certified for Continuing Medical Education credit.

^aNovo Nordisk will report all transfers of value, including meals, as required by law. Please refrain from consuming any meals available at this event if you are a healthcare provider licensed in a state that prohibits, or applies limits to, such interactions. Please contact NNI Ethics & Compliance with any questions at NNIComplianceassist@NovoNordisk.com.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, Novo Nordisk will not provide alcohol at its programs, and attendance at this program is limited to healthcare professionals with an educational need to receive the information. Additionally, attendance by guests or spouses is not appropriate and cannot be accommodated.

The content of this Product Theater and opinions expressed by the presenters are those of the sponsor or presenters and not those of the American Association for the Study of Liver Diseases.

Refreshments and the content of the Product Theater/Presentation are the sole responsibility of Novo Nordisk Inc.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2024 Novo Nordisk

All rights reserved.

US24SN00258

September 2024





In Pursuit of a Functional Cure for Hepatitis B: Monitoring Effectively, Optimizing Treatment, and Reducing the Risk of Complications

12:30 - 2:00 PM

Convention Center, Ballroom 20 D

SUPPORTED BY: GSK

ORGANIZED BY: PVI, PeerView Institute for Medical Education

CME: Maximum of 1.50 AMA PRA Category 1 Credits

PRESENTERS: Ira M. Jacobson, MD; Paul Kwo, MD, AGAF, FACG, FAASLD; Nancy S. Reau, MD

Despite safe, effective vaccines and antiviral treatments, HBV infection remains a major health concern. In this event from PeerView, experts explore HBV serologic testing for monitoring disease, evidence-based treatment to achieve a functional cure, and monitoring approaches for treatment response, disease progression, and detection of liver fibrosis, cirrhosis, and HCC.

LEARNING OBJECTIVES

- Explain the role of HBV serologic testing, including quantitative hepatitis B surface antigen (qHBsAg) testing, for monitoring disease activity and informing treatment of patients with hepatitis B infection
- Initiate evidence-based treatment of patients with chronic HBV infection to achieve a functional cure and reduce the risk of complications such as cirrhosis and HCC
- Implement expert-recommended monitoring approaches for treatment response, disease progression, and detection of liver fibrosis, cirrhosis, and HCC

[PeerView.com/SanDiego-HepB-Live](https://www.peerview.com/SanDiego-HepB-Live)

Rethinking MASH

12:30 - 2:00 PM

Convention Center, Ballroom 20A

SUPPORTED BY: Perspectum Ltd

ORGANIZED BY: HealthProMatch

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Claude Sirlin, MD; Niharika R. Samala, MD; Mark Dhinesh Muthiah, MBBS; Saima Ajaz, MD, MPhil, PhD

Since new nomenclature and novel treatments have been approved for MASH, there is a need for designing accurate pragmatic patient care pathways. This update focuses on the evidence-base behind precision markers and non-invasive tests in diagnosing, monitoring, and prognosticating patients with or at risk of MASH. This symposium also explores the challenges of a holistic



hosted by
HealthProMatch

LUNCH
PROVIDED

16TH NOV
12.30 - 2 PM (PST)

SAN DIEGO CONVENTION CENTER - ROOM **20A**

RETHINKING MASH



Presented for attendees of **THE LIVER MEETING® 2024.**

CATERED LUNCH SYMPOSIUM

SPEAKERS

- ▶ DR **CLAUDE SIRLIN** UC San Diego
- ▶ DR **NIHARIKA SAMALA** Indiana University
- ▶ DR **MARK DHINESH MUTHIAH** NUH Singapore
- ▶ DR **SAIMA AJAZ** Kings College London



REGISTER AT:

<https://healthpromatch.com/cme-event-nov-16/>



supported by



**1,5 CME
POINTS**



This event/function is provided by HealthProMatch and supported by Perspectum Ltd. This is not an official event/function of the American Association for the Study of Liver Diseases.



approach to MASH patients with competing comorbidities and multi-organ involvement as well as novel approaches involving lifestyle interventions.

LEARNING OBJECTIVES

- Understand new treatments available for MASH and analyze current evidence-base for non-invasive tests (NITs) in the diagnosis, monitoring and prognostication of patients with MASH
- Reflect on how new treatments, NITs, and PROMS in MASH can be incorporated into manageable patient pathways in primary and secondary care
- Reflect on how to manage competing risks in patients with MASH
- Consider the impact of MASH on population health and consider how non-pharmaceutical/ lifestyle interventions can be incorporated into patient pathways

<https://healthpromatch.com/cme-event-nov-16/>

LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today and Tomorrow?

7:30 - 9:30 PM

Marriott Marquis, Grand Ballroom 346 (Lobby Level)

SUPPORTED BY: AstraZeneca, Inc.

ORGANIZED BY: Physicians Education Resource

CME: Maximum of 2.0 AMA PRA Category 1 Credits

PRESENTERS: Richard S. Finn, MD; Pierre Gholam, MD; Anthony B. El-Khoueiry, MD; Lipika Goyal, MD

As the treatment landscape for hepatocellular carcinoma (HCC) continues to evolve, multidisciplinary, coordinated therapeutic intervention remains the cornerstone of care for these patients. Expert insights into treatment selection and collaborative decision-making are critical to informing and optimizing patient outcomes in resectable and unresectable disease. This hybrid Liver Cancer Tumor Board® symposium will bring together renowned experts in the management of HCC. In this educational program, these experts will share clinical insights and advances in the management of HCC with novel neoadjuvant, adjuvant, and perioperative immunotherapy-based therapeutic strategies.

LEARNING OBJECTIVES


- Assess the efficacy and safety of current and emerging adjuvant and neoadjuvant treatment strategies for early-stage resectable hepatocellular carcinoma (HCC) and appropriate patient selection

Primary Biliary Cholangitis Real-World Outcomes in Context

FRIDAY, NOVEMBER 15, 2024 | 12:45 PM – 2:00 PM PT

REGISTRATION AND MEAL: 12:15 PM | PRESENTATION: 12:45 PM

SAN DIEGO CONVENTION CENTER, 111 HARBOR DR
SAN DIEGO, CALIFORNIA | ROOM: BALLROOM 20 BC

HYBRID 

MODERATOR



Kris V. Kowdley MD, AGAF, FAASLD, FACP, FAGG
Director, Liver Institute Northwest
Professor of Medicine
Elson S. Floyd College of Medicine
Washington State University
Seattle, Washington, United States

FACULTY



David E. Jones, MD, PhD
Professor of Liver Immunology
Newcastle University
Newcastle, United Kingdom



Alejandra Maria Villamil, MD
Chief of Autoimmune Liver
Diseases Unit
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina

AGENDA

12:45 PM

Welcome and Introductions

Kris V. Kowdley MD, AGAF, FAASLD, FACP, FAGG

12:50 PM

Consequences of Untreated or Improperly Treated PBC

Kris V. Kowdley MD, AGAF, FAASLD, FACP, FAGG

1:00 PM

Goals of PBC Therapy

David E. Jones, MD, PhD

1:20 PM

Second-Line PBC Therapy

Alejandra Maria Villamil, MD

1:40 PM

Key Practical Takeaways

Kris V. Kowdley MD, AGAF, FAASLD, FACP, FAGG

1:45 PM

Audience Q&A

Kris V. Kowdley MD, AGAF, FAASLD, FACP, FAGG

2:00 PM

Conclude



Register Now!

For more information and to register, visit:

www.medscape.org/sympo/pbc-sandiego24

PRESENTED FOR ATTENDEES ATTENDING THE LIVER MEETING® 2024.
THIS EVENT IS PROVIDED BY MEDSCAPE EDUCATION AND SUPPORTED
BY INTERCEPT PHARMACEUTICALS, INC. THIS IS NOT AN OFFICIAL EVENT
OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.



- Analyze the efficacy and safety of current and emerging therapies and combinations for management of patients with intermediate stage and advanced/metastatic HCC
- Develop personalized care plans for patients with early-, intermediate-stage as well as advanced/metastatic HCC by integrating clinical trial evidence, expert guidelines, tumor characteristics, patient comorbidities, and goals of therapy
- Devise proactive plans for monitoring and mitigating treatment-related adverse events associated with current and emerging therapies for patients with HCC

<https://www.gotoper.com/courses/liver-cancer-meeting>

The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care

7:30 - 9:30 PM

Marriott Marquis, Grand Ballroom 125 (Lobby Level)

SUPPORTED BY: Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc.

ORGANIZED BY: Medtelligence

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Naim Alkhouri, MD, FAASLD, DABOM; Amreen M. Dinani, MD, FRCPC; Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAF

This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment monitoring for disease progression, and long-term medical management, including the role of incretin agonists.

LEARNING OBJECTIVES

- Summarize the pathophysiologic rationale for using obesity pharmacotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)
- Apply recommendations for the treatment of patients with MASLD/MASH with GLP-1 RAs
- Devise a multidisciplinary plan to manage obesity in patients with MASLD/MASH
- Interpret data from clinical trials of emerging liver-directed therapies for MASLD/MASH
- Interpret data from clinical trials of emerging anti-obesity therapies for MASLD/MASH

www.ReachMD.com/segment/26613


Free CME/CE Lunch Symposium


Provided By:

provaSM
EDUCATION

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient

Join us for best practices for applying advances in the diagnosis, treatment & management of MASLD/MASH.

 **November 17, 2024 | 12:30 PM - 2:00 PM PT**

 **San Diego Convention Center
111 W Harbor Dr, San Diego, CA 92101,
Ballroom 20A (Upper Level), United States**

 **VIRTUAL BROADCAST**

November 17, 2024 | 12:30 PM - 2:00 PM PT

This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management, including the role of incretin agonists.



[Register Now](#)

Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Prova Education and supported by Madrigal Pharmaceuticals. This is not an official event/function of the American Association for the Study of Liver Diseases.

Commercial Support:
This activity is supported by independent educational grants from Madrigal Pharmaceuticals.



Sunday, Nov. 17

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient

12:30 - 2:00 PM

Convention Center, Ballroom 20A

SUPPORTED BY: Madrigal Pharmaceuticals

ORGANIZED BY: Prova Education

CME: Maximum of 1.50 AMA PRA Category 1 Credits

PRESENTERS: Naim Alkhoury, MD, FAASLD, DABOM; Meena B. Bansal, MD, FAASLD; Mary E. Rinella, MD, FAASLD

This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment, monitoring for disease progression, and long-term medical management, including the role of incretin agonists.

LEARNING OBJECTIVES

- Take the appropriate action in a patient with risk factors for MASLD/MASH and a given risk stratification score
- Demonstrate best practices for management of patients with MASLD
- Select an appropriate treatment strategy for a patient with at-risk MASH

www.ReachMD.com/segment/26614

Alpha-1 Antitrypsin Deficiency: Are You Overlooking a Leading Genetic Culprit in Liver Disease?

12:30 - 2:00 PM

Convention Center, Ballroom 20 BC

SUPPORTED BY: Takeda Development Center Americas, Inc.

ORGANIZED BY: Clinical Care Options (CCO)

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Mark Brantly, MD; Virginia Clark, MD, MS; Pavel Strnad, MD; Jeffrey Teckman, MD

Alpha-1 antitrypsin deficiency associated (AATD) is a leading genetic cause of liver disease, yet it remains largely underdiagnosed and poorly understood. This interactive symposium features a multispecialty expert panel to provide insights into the pathophysiologic and genetic underpinnings, best practices in diagnosing, and navigating the management of AATD liver disease.

Challenging Cases in Navigating Diagnostic Complexities and Strategies for Improved Management of Adults With Cholestatic Liver Diseases

FRIDAY, NOVEMBER 15, 2024 | 8:00 PM – 9:30 PM PT

REGISTRATION AND MEAL: 7:30 PM | PRESENTATION: 8:00 PM

MARRIOTT MARQUIS SAN DIEGO MARINA, 333 W HARBOR DR
SAN DIEGO, CALIFORNIA | ROOM: MARRIOTT GRAND BALLROOM 125

HYBRID 

MODERATOR



Gideon Hirschfield, MB, BChir, PhD, FRCP
Professor of Medicine,
Gastroenterology and Hepatology
Toronto Centre for Liver Disease
Toronto General Hospital
Toronto, Ontario, Canada

FACULTY



Amal Aqul, MD
Associate Professor of Pediatrics
University of Texas Southwestern
Medical Center
Dallas, Texas



Raj Vuppalanchi, MD
Professor of Medicine
Director of Hepatology
Division of Gastroenterology
and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

AGENDA

Welcome and Introduction

Early and Timely Diagnosis of Rare Forms of Cholestasis in Adults

Case Challenge: Optimizing Management in Primary Biliary Cholangitis

Case Challenge: Diagnostic and Therapeutic Decision-Making—Progressive Familial Intrahepatic Cholestasis in Adults

Q&A

Concluding Remarks



Register Now!

For more information and to register, visit:
www.medscape.org/symposium/cholestatic-liver

PRESENTED FOR ATTENDEES ATTENDING THE LIVER MEETING® 2024.
THIS EVENT IS PROVIDED BY MEDSCAPE EDUCATION AND
SUPPORTED BY IPSEN. THIS IS NOT AN OFFICIAL EVENT OF THE
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.



LEARNING OBJECTIVES

- Identify clinical manifestations of AATD-LD
- Position recommended diagnostic procedures for suspected AATD-LD
- Implement noninvasive tests to assess liver fibrosis in patients with AATD-LD
- Summarize investigational therapeutic approaches for AATD-LD

<https://clinicaloptions.com/events/alpha-1-antitrypsin-deficiency-liver-disease/12491>

Monday, Nov. 18

Itching for More: Improving Care of Pruritus in PBC

12:30 - 2:00 PM

Convention Center, Ballroom 20 BC

SUPPORTED BY: GlaxoSmithKline

ORGANIZED BY: Clinical Care Options, LLC

CME: Maximum of 1.5 AMA PRA Category 1 Credits

PRESENTERS: Stuart C. Gordon, MD, FACP, FAGC, AGAF, FAASLD; Marlyn J. Mayo, MD; Pam Rivard, RN

Cholestatic pruritus can have devastating impacts on a patient's quality of life. This interactive symposium will feature expert hepatologists and a patient, offering insights into the burden of cholestatic pruritus in PBC, its impact on quality of life, current best practices for assessment and management, and emerging therapies.

LEARNING OBJECTIVES

- Assess the impact of cholestatic pruritus on quality of life for patients with PBC
- Create comprehensive treatment plans for patients with PBC and cholestatic pruritus, including ongoing assessment, non-pharmacologic and pharmacologic interventions
- Describe the potential role of emerging agents in therapy for cholestatic pruritus in PBC

www.clinicaloptions.com/2024PBCpruritusSanDiego




Scan the QR code to view the exhibitor list.

Discussing Key Clinical Decisions in Managing Primary Biliary Cholangitis

SATURDAY, NOVEMBER 16, 2024 | 12:45 PM – 2:00 PM PT

REGISTRATION AND MEAL: 12:15 PM | PRESENTATION: 12:45 PM

SAN DIEGO CONVENTION CENTER, 111 HARBOR DR
SAN DIEGO, CALIFORNIA | ROOM: BALLROOM 20 BC

HYBRID 

MODERATOR



Maria Morais, RN
Vice President
Patient Advocacy
Canadian PBC Society
Toronto, Ontario, Canada

FACULTY



Gideon Hirschfield, MB BChir, FRCP, PhD
Professor of Medicine,
Gastroenterology and Hepatology
Toronto Centre for Liver Disease
Toronto General Hospital
Toronto, Ontario, Canada



Sonal Kumar, MD, MPH
Director, General Gastroenterology
and Hepatology
Director, Innovative Center
for Health and Nutrition in
Gastroenterology (ICHANGE)
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York, United States

AGENDA

12:45 PM

Welcome and Introductions

12:50 PM

Addressing Key Clinical
Questions in PBC

- Assessing the Risk of Progression
- Setting Treatment Goals
- Managing Bothersome Symptoms

1:20 PM

Discussing Cases and Clinical
Decision-Making

- Case 1: Patient on First-Line
Therapy Not Having
a Complete Response
- Case 2: Patient on Combination
Therapy With UCDA and OCA

1:50 PM

Concluding Remarks
and Audience Q&A



Register Now!

For more information and to register, visit:
www.medscape.org/sympo/pbc-sandiego-24

PRESENTED FOR ATTENDEES ATTENDING THE LIVER MEETING® 2024.
THIS EVENT IS PROVIDED BY MEDSCAPE EDUCATION AND SUPPORTED
BY GILEAD SCIENCES, INC. THIS IS NOT AN OFFICIAL EVENT OF THE
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.



TLM Theaters

Sunday, Nov. 17

Discover a Treatment Option that Is Available for Patients With NASH With Liver Fibrosis

10:00 - 10:45 AM

Exhibit Hall B, TLM Theater 1

SUPPORTED BY: Madrigal Pharmaceuticals, Inc.

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with NASH, including the clinical data.

PRESENTERS: Sonal Kumar, MD, MPH; Sonja Olsen, MD

Key Considerations When Choosing a First-Line Treatment Option for Unresectable Hepatocellular Carcinoma

10:00 - 10:45 AM

Exhibit Hall B, TLM Theater 2

SUPPORTED BY: AstraZeneca

This presentation will cover important factors in selecting a first-line treatment option for patients with unresectable hepatocellular carcinoma (HCC). It will explore the efficacy and safety from a clinical trial, including the latest evidence from recent analyses.

PRESENTER: Pierre M. Gholam, MD

Experience The Park @ TLM | Sails Pavilion

This brand-new onsite experience is a vibrant networking hub, offering attendees a space to engage, collaborate, and recharge between sessions.

Alpha-1 Antitrypsin Deficiency

Are You Overlooking a Leading Genetic Culprit in Liver Disease?

Sunday, November 17, 2024



Lunch & Symposium
12:30 PM - 2:00 PM PT



San Diego Convention Center
111 W Harbor Drive, San Diego, CA 92101
Ballroom 20 BC



MARK BRANTLY,
MD



VIRGINIA CLARK,
MD, MS



PAVEL STRNAD,
MD



JEFFREY TECKMAN,
MD



Scan QR code to register or register at:
clinicaloptions.com/2024AATDSanDiego

Supported by an educational grant from Takeda Development Center Americas, Inc.

Itching for More

Improving Care of Pruritus in PBC

Monday, November 18, 2024



Lunch & Symposium
12:30 PM - 2:00 PM PT



San Diego Convention Center
111 W Harbor Drive, San Diego, CA 92101
Ballroom 20 BC



STUART C. GORDON, MD,
FACP, FAGC, AGAF, FAASLD



MARLYN J. MAYO,
MD



PAM RIVARD,
RN



Scan QR code to register or register at:
clinicaloptions.com/2024PBCpruritusSanDiego

This educational activity is supported by an educational grant from GlaxoSmithKline.

Joint Accreditation Statement



In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Presented for attendees of The Liver Meeting® 2024. This is not an official event/function of the American Association for the Study of Liver Diseases.

Provided by Clinical Care Options, LLC



powered by CEA



Addressing the Itch: HCP and Patient Perspectives on Managing Cholestatic Pruritus in PBC

12:30 – 1:00 PM

Exhibit Hall B, TLM Theater 1

SUPPORTED BY: GSK US Medical Affairs

Join leading experts in hepatology and a patient advocate for an engaging discussion to gain perspective on optimizing the management of cholestatic pruritus in primary biliary cholangitis (PBC). Learn about the patient burden of cholestatic pruritus, addressing gaps in assessment, and opportunities to take a more patient-centric approach to management.

PRESENTERS: Alan Bonder, MD, AGAF; Sonal Kumar, MD, MPH; Jeanine Mione, PBC Patient Advocate

Long-Term Data for GIVLAARI® (givosiran), including Clinical Case Reviews

12:30 – 1:00 PM

Exhibit Hall B, TLM Theater 2

SUPPORTED BY: Alnylam Pharmaceuticals

Please join Alnylam Pharmaceuticals and Dr. Bruce Wang as he reviews long-term efficacy and safety data for RNA interference (RNAi) therapeutic GIVLAARI® (givosiran), featuring published data from the complete 36-month ENVISION Phase 3 trial. Dr. Wang will also share patient cases from his practice to provide clinical perspective on treatment with GIVLAARI.

PRESENTER: Bruce Wang, MD

MASH Matters: The Evolving Management of Patients With Metabolic Dysfunction Associated Steatohepatitis

1:30 – 2:00 PM

Exhibit Hall B, TLM Theater 1

SUPPORTED BY: Boehringer Ingelheim International GmbH

MASH prevalence is rapidly increasing in parallel with increases in obesity and other cardio-renal-metabolic diseases. An interactive case will explore clinical challenges and unmet patient needs.

PRESENTER: Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD



hosted by
HealthProMatch

LUNCH
PROVIDED

15TH NOV
12.30 - 2 PM (PST)

SAN DIEGO CONVENTION CENTER - ROOM **20A**

UPDATES IN THE
PATIENT JOURNEY:
**PRIMARY
SCLEROSING
CHOLANGITIS &
AUTOIMMUNE
HEPATITIS**



Presented for attendees of **THE LIVER MEETING® 2024.**

CATERED LUNCH SYMPOSIUM

SPEAKERS

- ▶ DR **CRAIG LAMMERT** Indiana University
- ▶ DR **JOHN M. VIERLING** Baylor College of Medicine
- ▶ Ms **CYNTHIA BUNESS** Stanford University



REGISTER AT:

<https://healthpromatch.com/cme-event-nov-15/>



supported by



1,5 CME
POINTS



This event/function is provided by HealthProMatch and supported by Perspectum Ltd. This is not an official event/function of the American Association for the Study of Liver Diseases.

**Patient Spotlight: Hear From an Adult With Alagille Syndrome and Explore Clinical Insights With a Pediatric Hepatologist**

1:30 - 2:00 PM

*Exhibit Hall B, TLM Theater 2***SUPPORTED BY:** Mirum Pharmaceuticals

Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) are cholestatic liver diseases characterized by debilitating pruritus. In this session, Emma will share her perspectives as an adult with ALGS. In addition, Dr. Ajay Jain will examine the impact of cholestatic pruritus and the evolving treatment landscape.

PRESENTERS: Ajay Jain, MD; Emma Spalinger (ALGS)**A Deep Dive Into MASH: Exploring the Role of Metabolic Dysfunction in Disease Pathophysiology**

3:30 - 4:15 PM

*Exhibit Hall B, TLM Theater 1***SUPPORTED BY:** Novo Nordisk, Inc.

This presentation will examine MASH (metabolic dysfunction-associated steatohepatitis) and the role of cardiometabolic dysfunction in disease development and progression. We will also discuss current AASLD guidelines regarding screening and management of patients at high-risk for advanced disease.

PRESENTER: Naim Alkhouri, MD, FAASLD, DABOM**Optimizing the Treatment Pathway for Patients with PBC**

3:30 - 4:15 PM

*Exhibit Hall B, TLM Theater 2***SUPPORTED BY:** Intercept Pharmaceuticals, Inc.

Join us for an informative presentation that discusses liver health and taking treatment for Primary Biliary Cholangitis (PBC) a step further. Learn about an approved therapy for patients with PBC.

PRESENTER: Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD



FOR TREATMENT OF PORTAL HYPERTENSION ... TIME TO CONSIDER TIPS?

Earlier TIPS increases survival and reduces complications in patients with liver disease.^{1,2}



See the evidence at
[goremedical.com/rethinktips](https://www.goremedical.com/rethinktips)

1. Hernández-Gea V, Procopet B, Giraldez Á, *et al*; International Variceal Bleeding Observational Study Group and Baveno Cooperation. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. *Hepatology* 2019;69(1):282-293. <https://aasidpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30182>

2. Bureau C, Thabut D, Oberti D, *et al*. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. *Gastroenterology* 2017;152(1):157-163. <http://www.sciencedirect.com/science/article/pii/S0016508516351101> E

 Consult Instructions
for Use
[eifu.goremedical.com](https://www.eifu.goremedical.com)

INTENDED USE/INDICATIONS FOR USE: The GORE® VIATORR® TIPS Endoprosthesis is indicated for use in the de novo and revision treatment of portal hypertension and its complications such as variceal bleeding, gastropathy, refractory ascites and/or hepatic hydrothorax.

CONTRAINDICATIONS: There are no known contraindications for this device.

Refer to the *Instructions for Use* at [eifu.goremedical.com](https://www.eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only

W. L. Gore & Associates, Inc. Flagstaff, Arizona 86004 [goremedical.com](https://www.goremedical.com)

GORE, *Together, improving life* and designs are trademarks of W. L. Gore & Associates.

© 2024 W. L. Gore & Associates, Inc. 24PL1152-EN01 OCTOBER 2024

Together, improving life





Monday, Nov. 18

Rezdiffra (resmetirom) – A Treatment Option for Patients

10:00 – 10:45 AM

Exhibit Hall B, TLM Theater 1

SUPPORTED BY: Madrigal Pharmaceuticals, Inc.

Please join us for an engaging and highly anticipated educational presentation focusing on Rezdiffra and its clinical data.

PRESENTER: Mazen Nouredin, MD, MHSc

TERLIVAZ® (terlipressin): The First FDA-Approved Treatment for HRS in Adults With Rapid Reduction in Kidney Function

10:00 – 10:45 AM

Exhibit Hall B, TLM Theater 2

SUPPORTED BY: Mallinckrodt Pharmaceuticals

Consider treatment with the first and only FDA-approved drug for HRS in adults with rapid reduction in kidney function: TERLIVAZ® (terlipressin). Terlipressin is recommended by AASLD Guidance and ACG guidelines. Demonstrated a significantly higher rate of verified HRS reversal, defined as improvement in renal function, avoidance of dialysis, and short-term survival. Treatment earlier in disease progression was associated with a higher rate of HRS reversal and lower rate of respiratory failure. Terlipressin can be used to treat patients outside of the ICU on the regular medical floor. The most commonly observed adverse reactions in patients treated with terlipressin were abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea.

PRESENTER: Tien S. Dong, MD

The Genetic Architecture of SLD: Pioneering New Frontiers in Advanced Liver Disease

12:30 – 1:00 PM

Exhibit Hall B, TLM Theater 1

SUPPORTED BY: GSK

This panel will explore the genetic architecture of steatotic liver disease (SLD) and its impact on managing advanced liver disease. Experts will discuss unmet needs, key genetic drivers, like HSD17B13, how factors like alcohol and diet influence disease progression, and how genetics can shape the future therapeutic strategies for SLD.

PRESENTERS: Naga Chalasani; Maru Rinella

Monday, Nov. 18

Unlocking Treatment Possibilities in PBC

12:30 - 1:00 PM

Exhibit Hall B, TLM Theater 2

SUPPORTED BY: Ipsen Biopharmaceuticals, Inc.

Discover the latest in PBC advancements with Dr. Sammy Saab.

PRESENTER: Sammy Saab, MD, FAASLD

Shaping the Future: Clinical Validation of a Multi-Analyte Blood Test for Early HCC Detection

1:30 - 2:00 PM

Exhibit Hall B, TLM Theater 1

SUPPORTED BY: Helio Genomics

HelioLiver, an advanced blood test for early HCC detection, has shown superior performance over ultrasound, especially in identifying HCC lesions ≤ 4 cm. Join us to dive into these promising findings and their significant impact on the liver cancer landscape.

PRESENTER: Richard Van Etten, MD, PhD

Unraveling Genetic Causes of a Cholestatic Liver Disease and a Review of a Treatment Option

1:30 - 2:00 PM

Exhibit Hall B, TLM Theater 2

SUPPORTED BY: Ipsen Biopharmaceuticals, Inc.

Join us for a presentation starting with Dr. Amber Hildreth discussing genetic causes of cholestatic liver disease followed by Dr. Edward Mena with an overview of a possible treatment option for your pediatric and adult patients.

PRESENTERS: Amber Hildreth, DO; Edward Mena, MD, FAASLD



Point of Care Testing for HCV RNA: Innovating for Patient Impact Where and When it Matters

3:30 - 4:15 PM

Exhibit Hall B, TLM Theater 1

SUPPORTED BY: Cepheid

The introduction of first POC HCV RNA test in the U.S. is set to revolutionize HCV elimination programs! Join our expert panel as they dive into how this game-changing solution is enabling innovative models of care that reach more people, speeds up diagnosis, and improves linkage to care.

PRESENTERS: Jennifer Havens, PhD, MPN; Jacob Manteuffel, MD; Anthony Martinez, MD, FAASLD; David Persing, MD, PhD

Introducing a Novel, First-in-Class Treatment for Primary Biliary Cholangitis (PBC)

3:30 - 4:15 PM

Exhibit Hall B, TLM Theater 2

SUPPORTED BY: Gilead Sciences, Inc.

Join us for an informative product theater session on a recent FDA-approved treatment option for primary biliary cholangitis (PBC). Discover how this novel therapy may improve PBC outcomes for appropriate patients affected by this chronic liver disease.

PRESENTER: John Vierling, MD, FACP, FAASLD, AGAF

Stay Connected

Follow AASLD on social media and use the official hashtag **#TLM24** to connect with fellow attendees online.





NOW FDA APPROVED!

Come see how LIVDELZI is
different at our product theater
on Monday, November 18
at 3:30 PM PST.

To learn more,
stop by Booth #727



Scan here to visit
LivdelziHCP.com



LIVDELZI, the LIVDELZI Logo, GILEAD, and
the GILEAD Logo are trademarks of Gilead
Sciences, Inc., or its related companies.

© 2024 Gilead Sciences, Inc. All rights
reserved. US-LIVP-0103 10/24